AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Chief Executive Officer Pascal Soriot buys 20,000 shares at GBP102.03, worth GBP2.0 million, on Thursday.

AstraZeneca has allocated $3.5billion to expand its US manufacturing and research footprint by the end of 2026. The funding ...

Cambridge: AstraZeneca has announced $3.5 billion of capital investment in the United States focused on expanding the Company ...

Astrazeneca has recently announced 3.5 billion dollars of capital investment in the United States focused on expanding the ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca said it plans to pump $2 billion in new investment ... The new spending will be for a research-and-development ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...